14.50 and 69.07 ± 8.28 years, and average length of stay for 9.41 ± 4.45 and 9.17 ± 4.55 days, respectively. Most procedures were conducted at medical centers (45.52% and 37.57%). The most frequent diagnoses for THR are avascular necrosis (45.22%) and osteoarthritis (44.05%); while for TKR is osteoarthritis (96.42%). Only 40 THR (3.90%) and 160 TKR (6.66%) had ever been prescribed antithrombotic agents after surgeries, and mostly used aspirin alone (18 THR and 95 TKR). CONCLUSIONS: According to this nationwide individual patient dataset, antithrombotic agents are not commonly used after THR and TKR in Taiwan, but aspirin is the most frequently prescribed of all. These fi ndings deviate from the recommendations of current international guidelines. To establish Taiwanese own guidance, it is necessary to further investigate the effectiveness and safety of prophylactic antithrombotic agents after THR and TKR, and explore the infl uences of reimbursement policy and genetic factors on these outcomes.
DU4

COST-EFFECTIVENESS ANALYSIS OF TRAVOPROST FOLLOWED BY FIXED COMBINATION TRAVOPROST/TIMOLOL TREATMENT SEQUENCE (T-TTFC) COMPARED TO LATANOPROST FOLLOWED BY LATANOPROST/TIMOLOL FIXED COMBINATION (L-LTFC) FOR PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN MALAYSIA AND INDIA
Taylor M 1 , Tan R 2 1 York Health Economics Consortium, York, UK; 2 Alcon Laboratories R&D International, Singapore OBJECTIVES: To assess the cost-effectiveness of T-TTFC compared with L-LTFC treatment sequences for patients with open angle glaucoma or ocular hypertension (OHT) using a payer perspective in Malaysia and India. METHODS: A Markov model simulated the disease progression of open angle glaucoma and ocular hypertension (OHT) patients in India and Malaysia. Transition probabilities were obtained from Denis (2008) , and extrapolated from two phase III clinical trials (Topouzis, 2007; Netland; 2001) . Probabilities to develop new visual fi eld defect (VFD) was estimated from literature (Denis, 2004) . Utilization patterns were derived from local hospitals and literature. Unit costs were obtained from list prices. The time horizon was 5 years and sensitivity analyses were performed on key parameters. RESULTS: At 5 years, fewer T-TTFC patients switched to third line treatment, and 65.5% of patients showed no disease progression (no new VFDs) compared to 61.4% for L-LTFC Thus initiation of treatment in an OHT patient with T followed by TTFC if needed would avoid one incidence of VFD in every 24 incident cases (Number Needed to Treat-NNT). In Malaysia, T-TTFC results in a cost-savings of 1286 RM (US$378) against L-LTFC. In India over a 5-year period, T-TTFC results in a cost savings of 11,184 INR (US$243) against L-LTFC. Sensitivity analyses have demonstrated the robustness of these fi nding. CONCLUSIONS: From the payer perspective, T-TTFC yielded costsavings and fewer treatment switches. Poor IOP control results in therapy changes and increases the probability of patients experiencing new VFDs (Denis 2004), which in turn adversely impacts patient quality of life. Our savings estimates are conservative because potential cost savings, as a consequence of fewer ophthalmologist visits, particularly for patients who use private healthcare facilities, have not been captured. With these fi ndings policy-makers and clinicians should consider the use of T-TTFC for glaucoma patients as potential cost-saving medications. HE1  A CROSS-COUNTRY COMPRASION OF HEALTH PERFORMANCE  BETWEEN TAX-FUNDED AND SOCIAL HEALTH INSURANCE SYSTEM:  THE CHANNEL VIA PREVENTIVE CARE Chen Q, Li L Peking University, Beijing, China OBJECTIVES: Tax-funded system and the social health insurance (SHI) system are two main choices for health-care system reform. This research investigates the differences of health outcome and health expenditure between these two systems. The channels of such differences are also valuable for policymaker. We further explore the channel via public health and preventive care investment that leads to these differences. We are also interested in the impact of fi scal and political decentralization on health systems. METHODS: We merge the data from a variety of sources including WHO, the World Bank, OECD together with database prepared by independent researchers like Polity IV and Government Performance Indicator. After controlling the variables indicating the social-economic situations, we implement the Pooled-OLS Method and Fix-Effect Method for panel data. Then check the model specifi cation by testing the autocorrelation of the residuals. RESULTS: When the share of SHI in public health expenditure increases, the total health expenditure (THE) measured as its share in GDP increase dramatically. However, if there is local responsibility, this negative impact will be mitigated. What's more, the increase of SHI share also plays down the life expectancy, but with local responsibility the negative impact can get amended. It is worth the attention that the public health performance, measured by the share of expenditure in THE and a series of public health behaviors including the immunization rates and infectious disease incidences, presents a consistent pattern. That is, with the increase of the SHI share, the public health performance is weakened, but with local responsibility, the performance will be improved to some extent. CONCLUSIONS: Tax-funded system is more effi cient in the sense of cost-benefi t, and public health and preventive care investment are important channels of these different performances between the two types of health-care system.
PODIUM SESSION II: HEALTH EXPENDITURE STUDIES
HE2 NEW DRUGS AND THE GROWTH OF HEALTH EXPENDITURE: EVIDENCE FROM DIABETIC PATIENTS IN TAIWAN
Liu YM 1 , Hsieh CR 2 1 National Cheng Kung University, Tainan, Taiwan; 2 Academia Sinica, Taipei, Taiwan OBJECTIVES: The aim of this paper is to investigate whether the adoption of pharmaceutical innovation increases the overall expenditure on health care by focusing on diabetic patients. METHODS: By examining the National Health Insurance sampling longitudinal claims data between 2000 and 2004, we use a new class of drugs, namely, thiazolidinediones (TZD), as an example to investigate the effect on health expenditure of prescribing new drugs to patients by decomposing the impact into treatment substitution and treatment expansion effects. The difference-in-difference approach was used to estimate the effects of adopting new drugs by comparing the difference between the users of TZD drugs (the treatment group) and the nonusers of TZD drugs (the control group) as well as the difference between the pre and post periods. RESULTS: Our results indicate that the introduction of new drugs mainly impacts the outpatient drug expenditure and does not give rise to any offsetting effect on other outpatient and inpatient health expenditures. This suggests that the adoption of pharmaceutical innovation in treating diabetic patients is expenditure-increasing. In addition, we fi nd evidence that the treatment substitution channel has a more signifi cant impact on health expenditure than the treatment expansion channel. CONCLUSIONS: An important policy implication for our fi nding is that new prescription drugs do not pay for themselves, suggesting that the justifi cation for increasing health expenditure on the treatment of diabetes is not conditional upon a lowering in the demand for other types of health-care services. By contrast, it is conditional upon the increased health benefi ts per se.
HE3 ANALYSIS OF AN AFFORDABLE PRICE FOR PERFORMANCE-BASED RISK SHARING SCHEME: OMALIZUMAB ADAPTATION IN KOREA
Kim S, Kim J, Kim J, Kim C, Shin K, Kim K, Kim H Novartis Korea, Seoul, Seoul, South Korea OBJECTIVES: The innovative but expensive biologic agents are introduced in recent years, Korea government is meeting with diffi culty in funding for these agents due to limited health-care budget. Pay for performance as risk sharing scheme has been adopted to overcome this situation in other countries. In this article we tried to fi nd an affordable price based upon a budget neutral concept and adapted to risk sharing of Omalizumab. METHODS: Omalizumab, for treatment of moderate to severe allergic asthma, is only treated for responders at 16 weeks. We modeled the performance-based risk sharing along four assumptions: 1) no additional national healthcare budget, budget of risk sharing ≤ budget of no risk sharing; 2) positive manufacturer's profi t; 3) reimbursed only for responders at 16 weeks; and 4) manufacturer funding to responder in screening period. We also simulated the model by changing of input parameters. RESULTS: We defi ned and analyzed the function of risk sharing scheme based on national health-care budget and manufacturer's profi t. Lower boundary of affordable price was derived from the minimum of acceptable predicted sales volume for manufacturer and upper was calculated by a point of budget neutral. Lower boundary was highly depends on unit selling price, production cost and projected vials. Upper boundary was infl uenced more by total target patients, response rate, and expected price with no risk sharing. CONCLUSIONS: The concept of performance-based payment is a risk sharing between the payer and manufacturer for high-quality of new agent, and improves to patient's quality of life within the available national health-care budget. We show that the range of affordable price is calculated by a manufacturer's profi t and neutral point of health-care budget in the performance-based risk sharing and discuss potential challenges. To further analyze the effect of generic grouping, we classifi ed the branded drug into three categories patented branded drug, off-patent branded drug with no competitive generic drug and off-patent branded drug with competitive drug. RESULTS: We found that from 1999 to 2007, the annual growth rate of pharmaceutical expenditure was 6.0%; outpatient 6.3% and inpatient 5.5%. During the study period, the sales of the patented branded drugs rose from 20.5% to 30.9% with the highest increasing rate. The sales of the off-patent branded with competitive generic drugs and generic without the BA/BE testing drugs fell from 21.1% to 18.6% and from 39.3% to 28.4%, respectively. The sales volume in terms of DDD also has the same pattern as the drugs sales. Regarding the impact of drug price adjustment on Hospital, we found the share of drug claim by medical centers rose from 35.5% to 41.3%; regional hospitals from 25.3% to 30.2%, however local hospitals and primary health care decreased their share. In terms of fi rms, the IRPMA group held the highest increasing rate on share and importers held the lowest. CONCLUSIONS: The generic grouping price adjustment policy has effectively reduced the off-patent branded drug expenditure. However, total drug expenditure didn't decrease due to the increased expenditure of the new drugs with high prices.
HE4
POSTER SESSION CANCER -Clinical Outcomes Studies
PCN1 THE EVALUATION OF ADR ONLINE REPORTING OF RADIOPAQUE AGENTS IN A UNIVERSITY HOSPITAL IN TAIWAN
Huang CY, Hsieh YW, Lin WL, Wu HC China Medical University Hospital, Taichung, Taiwan OBJECTIVES: Radiopaque agents induce ADR frequently. But the numbers of ADR reporting are less than actual happening because of heavy workload on medical staffs. We created a simple and convenient online reporting system to replace paper report in our hospital. The aim of this study was to assess the variation of reporting rate. METHODS: In the system, the cases reported by physician including medication used, time of ADR come up and description of ADR event. We downloaded the data of patients who administrated radiopaque agents retrospectively as the base of study group, and observed the reporting rate of online reporting system from 2008 July to 2009 June (i.e., intervention group), comparing it with the paper report in 2007. RESULTS: There are fi ve radiopaque agents with four nonionic and 1 ionic contrast media (e.g., Gadobenate Dimeglumine, Iodixanol, Iohexol, Ioversol and Urografi n) used in our hospital. We received 20 ADR reports within 22,754 prescriptions of radiopaque agents from January to December in 2007 and 62 ADR reports in 29,840 prescriptions from 2008 July to 2009 June. The reporting rate elevated 2.3 times (0.09% to 0.21%) when we shifted paper reporting to online reporting system. In the intervention group, more than half ADR reports were rash and no serious side effects (e.g., nephrotoxicity, anaphylactic shock) had been reported. CONCLUSIONS: ADR report is important in patient safety and pharmacovigilance issues. In clinical practice, staff may miss to report ADR because of enormous amount of work load. If the reporting system is more user-friendly, it would be closer to the true incidence of adverse events which have been reported.
PCN2 ASSESSMENT ON THE DECREASING USE OF NARCOTIC ANALGESICS BY USING CANCER PAIN ADJUVANTS
Chen CH 1 , Chen KT 2 , Chen HY 3 , Hou MF 4 , Huang YB 4 , Chan AL 1 1 Chi Mei Medical Center, Tainan, Taiwan; 2 Chi-Mei Medical Center, Tainan, Taiwan; 3 Chi-Mei Medical Center, Liou Ying, Tainan, Taiwan; 4 Kaohsiung Medical University Chung-Ho Memorrial Hospital, Kaohsiung, Taiwan OBJECTIVES: Narcotic analgesic was usually used to relieve cancer pain in the past decades. Recently, co-analgesics with adjuvant drugs have become an essential way and successful alternatives for holistic care. The aim of this study is to assess the outcome of using cancer pain adjuvants. METHODS: This is an observational study.
Cancer patients with pain score > 3 were recruited from three medical centers in Taiwan. Numeric Pain Rating Scale, Wong-Baker Face Pain Rating Scale and Brief Pain Inventory were used to evaluate the differences of pain control between two groups, addition of pain adjuvants and narcotics. The monthly consumption of narcotics, the frequency of breakthrough pain and adverse event were recorded for analysis by Paired t-test. RESULTS: A total of 120 patients were eligible in this study. Fifty-fi ve (45.8%) and 65 (54.2%) patients received narcotic analgesics and pain adjuvants for pain control, respectively. The satisfaction of patients in both groups on pain control improved 2.03 ± 1.87 points in the narcotics group and 2.14 ± 1.72 points in concomitant adjuvants group without signifi cant difference. (F1,118 = 0.1024, P = 0.7495) The times of breakthrough pain was signifi cantly decreased in adjuvants group as compared to narcotics group(−1.47 ± 2.23 vs. −0.48 ± 1.80; F1,118 = 7.3556, P = 0.0077). CONCLUSIONS: No signifi cant difference in total consumption of narcotics and pain control was founded. The frequency of breakthrough pain is likely to be improved in the concomitant adjuvants as compared in the narcotics group. The study found the safety of adjuvant therapy do no harm to palliative patients.
PCN3 RANDOMIZED, PLACEBO, CONTROLLED, DOUBLE-BLIND TRIAL OF MELATONIN IN CHOLANGIOCARCINOMA PATIENTS
Manprasert W 1 , Johns NP 1 , Sookprasert A 1 , Kantpittaya J 1 , Johns J 1 , Konsil J 1 , Weerapreeyakul T 2 , Phongthai P 2 , Porasutpathana S 1 , Laolukana W 2 1 Khon Kaen University, Muang, Khon Kaen, Thailand; 2 Khon Kaen Hospital, Muang, Khon Kaen, Thailand OBJECTIVES: Cholangiocarcinoma is a leading cause of cancer death in the Northeast of Thailand. Currently, chemotherapy and supportive care are the main treatments in non-resectable cholangiocarcinoma patients. Many adverse events (AE) from disease and treatments have been reported that affect quality of life (QOL) of the patients. This study evaluated the effi cacy of melatonin compared to placebo on the QOL, AE and survival time. METHODS: The study was a randomized, double-blind, placebo, controlled trial. The patients received treatment following the protocol of each hospital, and the study drug. Patients were randomized by mixed-block randomization stratifi ed by hospital and type of treatment. The treatment group received melatonin (20 mg/day) and the control group received placebo. Patients started taking the study drug on the fi rst day of the treatment and continued for 3 months. QOL was assessed using Thai Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-HEP) and AE were assessed using Common Toxicity Criteria Adverse Events (CTCAE). RESULTS: There were 30 patients recruited in the study, divided into 15 patients in each group. Baseline characteristics of the two groups were not different. The melatonin group had a higher but not signifi cant percentage of improvement in FACT-Hep scores than the control in both the fi rst (20% vs. 6.7%) and second (20% vs. 6.7%) month. Median survival was longer in the melatonin group (160 vs. 130 days, P > 0.05). In addition, there were fewer reports of Grade 3-5 AE in the melatonin group than placebo in terms of anorexia (11% vs. 50%), fatigue (11% vs. 50%), nausea/vomiting (0% vs. 10%) and weight loss (0% vs. 20%). CONCLUSIONS: The combination of melatonin with standard treatment did not prolong overall survival. However, the melatonin treatment can decrease AE and maintain quality of life of non-resectable cholangiocarcinoma patients. Further studies with larger samples are needed.
PCN4 CANCER SYMPTOM SURVEY AND RELIABILITY ANALYSIS
Li P Peking University School of Oncology, Beijing, China OBJECTIVES: Through symptom survey in cancer patients to fi nd out the symptom distribution and patients treatment require. Also validate set of symptom items that are most commonly used in Traditional Chinese Medicine (TCM). METHODS: Use M. D. Anderson Symptom Assessment Inventory (MDASI) that previously validated Chinese version. Add 10 TCM items. We also asked the questions about using TCM request in cancer care. A multi center cross-sectional study using a convenience sample of 340 patients were conducted in 3 hospitals in Beijing and Dalian. Statistical use Spss and Excel software. Self evaluate questioner with Cronbach's Alpha score.
RESULTS:
The most severe symptoms were fatigue 89.4%, sleeping disturbance 74.4%, moth drier 72.9%, and poor appetite 72.9%, forgotten 71.2%. The infl uence of cancer symptoms to work, mood and activity were 89.7%, 82.6%, 78.6% separately. The quality of life was affected severely. 80% patients want to regulate the body with TCM. Almost 100% patients hope to know the knowledge of integrated TCM and western medicine, and the effect of TCM treatment cancer and health recover. Cronbach's Alpha score indicated acceptable internal consistency both the MDASI and TCM items, 0.86 for MDASI, 0.78 for TCM, 0.9 for MDASI_TCM 23 items. CONCLUSIONS: Fatigue, sleep disturbance, moth drier, poor appetite and forgotten are more severe symptoms in our cancer patient's survey. Greatly affect the quality of life of patients. There are an extremely request that TCM holism regulation in cancer patients. The MDASI and its TCM model could a critical tool to measure the effectiveness of TCM in cancer symptom management.
